A Clinical Review on Extreme Hypofractionated Stereotactic Body Radiation Therapy for Localized Prostate Cancer Using Nonrobotic Linear Accelerators

REFERENCES

• Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009;74(5):1405–1418.
   PubMed Web of Science ®Google Scholar
• Pahlajani N, Ruth KJ, Buyyounouski MK, Chen DYT, Horwitz EM, Hanks GE, Price RA, Pollack A. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(5):1949–56.
   PubMed Web of Science ®Google Scholar
• Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 2012;82(1):e17–24.
   PubMedGoogle Scholar
• Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol Lond Engl 2013;8(1):118.
   PubMedGoogle Scholar
• King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, Meier R, Wang J, Kupelian P, Steinberg M, Katz A. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol J Eur Soc Ther Radiol Oncol 2013;109(2):217–221.
   PubMed Web of Science ®Google Scholar
• King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;82(2):877–882.
   PubMed Web of Science ®Google Scholar
• Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, Hanscom HN, Laing S, Kim JS, Lei S, Batipps GP, Kowalczyk K, Bandi G, Pahira J, McGeagh KG, Collins BT, Krishnan P, Dawson NA, Taylor, KL, Dritschilo A, Lynch, JH, Collins SP. Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol Lond Engl 2013;8(1):58.
   PubMedGoogle Scholar
• Oliai C, Lanciano R, Sprandio B, Yang J, Lamond J, Arrigo S, Good M, Mooreville M, Garber B, Brady LW. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol 2013;2(1):63–70.
   PubMedGoogle Scholar
• Meier R, Kaplan I, Beckman A, Henning G, Woodhouse S, Williamson S, Mohideen N, Herold D, Cotrutz C, Sanda M. Stereotactic body radiation therapy for intermediate-risk organ-confined prostate cancer: interim toxicity and quality of life outcomes from a multi-institutional study. Int J Radiat Oncol 2012;84(3):S148.
   Web of Science ®Google Scholar
• Sahgal A, Roberge D, Schellenberg D, Purdie TG, Swaminath A, Pantarotto J, Filion E, Gabos Z, Butler J, Letourneau D, Masucci GL, Mulroy L, Bezjak A, Dawson LA, Parliament M. The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. Clin Oncol R Coll Radiol G B 2012;24(9):629–639.
   PubMedGoogle Scholar
• Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007;67(4):1099–1105.
   PubMed Web of Science ®Google Scholar
• Tang CI, Loblaw DA, Cheung P, Holden L, Morton G, Basran PS, Tirona R, Cardoso M, Pang G, Gardner S, Cesta A. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol R Coll Radiol G B 2008;20(10):729–737.
   PubMed Web of Science ®Google Scholar
• Loblaw A, Cheung P, D'Alimonte L, Deabreu A, Mamedov A, Zhang L, Tang C, Quon H, Jain S, Pang G, Nam R. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol J Eur Soc Ther Radiol Oncol 2013;107(2):153–158.
   PubMed Web of Science ®Google Scholar
• Menkarios C, Vigneault É, Brochet N, Nguyen DHA, Bahary J-P, Jolicoeur M, Beauchemin M-C, Villeneuve H, Van Nguyen T, Fortin B, Lambert C. Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a phase I/II trial. Radiat Oncol Lond Engl 2011;6:112.
   PubMed Web of Science ®Google Scholar
• Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie X-J, Yan J, Foster R, Pistenmaa D, Perkins A, Cooley S, Timmerman R. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 2011;29(15):2020–2026.
   PubMed Web of Science ®Google Scholar
• Mantz CA, Fernandez E. Real-time target tracking prostate SBRT: quality of life and disease outcomes from a phase II trial. Int J Radiat Oncol Biol Phys 2012;84(3):S368–S368.
   Web of Science ®Google Scholar
• Alongi F, Cozzi L, Arcangeli S, Iftode C, Comito T, Villa E, Lobefalo F, Navarria P, Reggiori G, Mancosu P, Clerici E, Fogliata A, Tomatis S, Taverna G, Graziotti P, Scorsetti M. Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiat Oncol Lond Engl 2013;8(1):171.
   PubMedGoogle Scholar
• Macias VA, Blanco ML, Perez-Romasanta LA. Initial experience with stereotactic body radiation therapy for localized prostate cancer using helical tomotherapy. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex 2013; [Epub ahead of print] PMID:23928833.
   Google Scholar
• Katz A. CyberKnife Radiosurgery for Prostate Cancer. [Internet]. TCRT. 2013, 463–472. Availablet from: http://www.crt.org/ c4309/CyberKnife-Radiosurgery-for-Prostate-Cancer-463–472-p 17811.html
   Google Scholar
• Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, Carver B, Coleman J, Lovelock M, Hunt M. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012;84(1):125–129.
   PubMed Web of Science ®Google Scholar
• Crehange G, Mirjolet C, Gauthier M, Martin E, Truc G, Peignaux-Casasnovas K, Azelie C, Bonnetain F, Naudy S, Maingon P. Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 2012;103(2):244–246.
   PubMed Web of Science ®Google Scholar
• Takeda K, Takai Y, Narazaki K, Mitsuya M, Umezawa R, Kadoya N, Fujita Y, Sugawara T, Kubozono M, Shimizu E, Abe K, Shirata Y, Ishikawa Y, Yamamoto T, Kozumi M, Dobashi S, Matsushita H, Chida K, Ishidoya S, Arai Y, Jingu K, Yamada, S. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan. Radiat Oncol Lond Engl 2012;7:105.
   PubMedGoogle Scholar
• Aluwini S, van Rooij P, Hoogeman M, Kirkels W, Kolkman-Deurloo I-K, Bangma C. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol Lond Engl 2013;8:84.
   PubMed Web of Science ®Google Scholar
• Bolzicco G, Favretto MS, Scremin E, Tambone C, Tasca A, Guglielmi R. Image-guided stereotactic body radiation therapy for clinically localized prostate cancer: preliminary clinical results. Technol Cancer Res Treat 2010;9(5):473–477.
   PubMed Web of Science ®Google Scholar
• Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 2002;60(4):650–655.
   PubMed Web of Science ®Google Scholar
• Tsumura H, Satoh T, Ishiyama H, Tabata K, Kotani S, Minamida S, Kimura M, Fujita T, Matsumoto K, Kitano M, Hayakawa K, Baba S. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial. Int J Radiat Oncol Biol Phys 2011;81(4):e385–e392.
   PubMed Web of Science ®Google Scholar
• Prosnitz RG, Schneider L, Manola J, Rocha S, Loffredo M, Lopes L, D'Amico AV. Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study. Int J Radiat Oncol Biol Phys. 1999;45(3):563–566.
   PubMed Web of Science ®Google Scholar
• Fuccio L, Guido A, Laterza L, Eusebi LH, Busutti L, Bunkheila F, Barbieri E, Bazzoli F. Randomised clinical trial: preventive treatment with topical rectal beclomethasone dipropionate reduces post-radiation risk of bleeding in patients irradiated for prostate cancer. Aliment Pharmacol Ther 2011;34(6):628–637.
   PubMed Web of Science ®Google Scholar
• Van Lin ENJT, Kristinsson J, Philippens MEP, de Jong DJ, van der Vight LP, Kaanders JH, Leer JW, Visser AG. Reduced late rectal mucosal changes after prostate three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy. Int J Radiat Oncol Biol Phys 2007;67(3):799–811.
   PubMed Web of Science ®Google Scholar
• King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009;73(4):1043–1048.
   PubMed Web of Science ®Google Scholar
• Quon H, Loblaw DA, Cheung PCF, Holden L, Tang C, Pang G, Morton G, Mamedov A, Deabreu A. Intra-fraction motion during extreme hypofractionated radiotherapy of the prostate using pre- and post-treatment imaging. Clin Oncol R Coll Radiol G B 2012;24(9):640–645.
   PubMed Web of Science ®Google Scholar